[Transformation from Promyelocytic Leukemia with T (15; 17) ( Q22; Q21) to Acute Monocytic Leukemia with T (11; 17) (q23; Q21) in a Case].

Zheng Wang,Ye Li,Hui Dang,Yan Shi,Qi He,Lin Feng,Li Bao,Yazhen Qin,Yanrong Liu,Xiaojun Huang,Yueyun Lai
DOI: https://doi.org/10.3760/cma.j.issn.1003-9406.2018.02.030
2018-01-01
Abstract:OBJECTIVE:To report on a case of therapy-related acute monocytic leukemia(t-AML) with t(11;17) (q23;q21)/MLL-AF17q after successful treatment for acute promyelocytic leukemia(APL) with t(15;17) (q22;q21)/PML-RARα.METHODS:A MICM method (bone marrow morphology(M), immunophenotype(I), cytogenetics(C), and molecular biology(M)) was used for the diagnosis and classification of the disease at the time of onset and transformation.RESULTS:The patient was initially identified with typical morphology and immunophenotype of APL. She has carried t(15;17)(q22;q21) and PML-RARα fusion gene but was without t(11;17)(q23;q21) or MLL gene abnormalities. After 13 months of successful treatment, she has transformed to AML with typical morphology and immunophenotype. t(11;17)(q23;q21) and MLL-AF17q fusion gene were detected in her bone marrow sample, while no PLZF-RARα fusion gene was detected by real-time quantitative reverse-transcription PCR(RQ-PCR) and fluorescence in situ hybridization(FISH).CONCLUSION:t-AML is a serious complication after successful treatment of APL. t(11;17)(q23;q21) is not specific for the diagnosis of variant APL and can also be detected in t-AML. RQ-PCR and FISH are essential for the diagnosis of such patients.
What problem does this paper attempt to address?